CoChat
Sign Up
Cited by 629Treatment of Major DepressionNeurotransmitter Receptor Influence on BehaviorNeuroscience and Neuropharmacology Research

The DOI matches its Crossref record; 198 of the 203 references it cites were found in a registry or an index.

Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review

Vaswani, Meera, Linda, Farzana Kadar, Ramesh, Subramanyam·2003·Progress in Neuro-Psychopharmacology and Biological Psychiatry
DOI 10.1016/s0278-5846(02)00338-x
Open this paper in CoChat — free account

Abstract

The selective serotonin reuptake inhibitors (SSRIs) have emerged as a major therapeutic advance in psychopharmacology. As a result, the discovery of these agents marks a milestone in neuropsychopharmacology and rational drug design, and has launched a new era in psychotropic drug development. Prior to the SSRIs, all psychotropic medications were the result of chance observation. In an attempt to develop a SSRI, researchers discovered a number of nontricyclic agents with amine-uptake inhibitory properties, acting on both noradrenergic and serotonergic neurons with considerable differences in potency. A given drug may affect one or more sites over its clinically relevant dosing range and may produce multiple and different clinical effects. The enhanced safety profile includes a reduced likelihood of pharmacodynamically mediated adverse drug-drug interactions by avoiding affects on sites that are not essential to the intended outcome. SSRIs were developed for inhibition of the neuronal uptake pump for serotonin (5-HT), a property shared with the TCAs, but without affecting the other various neuroreceptors or fast sodium channels. The therapeutic mechanism of action of SSRIs involves alteration in the 5-HT system. The plethora of biological substrates, receptors and pathways for 5-HT are candidates to mediate not only the therapeutic actions of SSRIs, but also their side effects. A hypothesis to explain these immediate side effects is that 5-HT is increased at specific 5-HT receptor subtypes in discrete regions of the body where the relevant physiologic processes are regulated. Marked differences exist between the SSRIs with regard to effects on specific cytochrome P450 (CYP) enzymes, and thus the likelihood of clinically important pharmacokinetic drug-drug interactions. Although no clear relationship exists between the clinical efficacy, plasma concentration of SSRIs, nor any threshold that defines toxic concentrations, but therapeutic drug monitoring (TDM) may be useful in special populations, such as in elderly patients, poor metabolizers (PM) of sparteine (CYP2D6) or mephenytoin (CYP2C19), and patients with liver and kidney impairment. Several meta-analyses have reviewed the comparative efficacy of TCAs and SSRIs, and concluded that both TCAs and SSRIs have similar efficacy in the treatment of depression. SSRIs have demonstrated better efficacy and tolerability in the treatment of obsessive compulsive disorder (OCD). They have also been found to be effective in the treatment for social anxiety disorder both in reducing total levels of social anxiety and in improving overall clinical condition. The benefit of SSRIs in anorexia nervosa (AN) is apparently short-term unless medication is given in the context of nutritional or behavioral therapy. No single antidepressant can ever be recommended for every patient, but in a vast majority of patients, SSRIs should be considered as one of the first-line drugs in the treatment of depression.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0278-5846(02)00338-x

Cites

198 of 198 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Research works printed but not linked: 6

  1. Bauman, 1995, The pharmacokinetics of citalopram, Rev. Contemp. Pharmacother., 6, 287
  2. Geddes, 2000, SSRIs versus other antidepressants for depressive disorder, Cochrane Database Syst. Rev., 2
  3. Mendels, 1995, Sertraline, vol. 2, 2073
  4. Preskorn, 1991, Therapeutic drug monitoring for antidepressants: efficacy, safety and cost effectiveness, J. Clin. Psychiatry, 52, 23
  5. Spigset, 1997, Non-linear fluvoxamine disposition and relation to some CYP activities, Eur. J. Clin. Pharmacol., 52, A172
  6. van der Kolk, 1994, Fluoxetine in posttraumatic stress disorder, J. Clin. Psychiatry, 55, 517

Cited by

Sorted by citations

See all 629

Related

See all

Metadata

Authors
Vaswani, M., Linda, F. K., & Ramesh, S.
Affiliations
All India Institute of Medical Sciences (IN)
Corresponding author
Vaswani, Meera
Venue
Progress in Neuro-Psychopharmacology and Biological Psychiatry
Publisher
Elsevier BV
Published
2003-02
Volume
27
Issue
1
Pages
85-102
ISSN
0278-5846 (ISSN-L)
DOI
10.1016/s0278-5846(02)00338-x
OpenAlex
W1988612597
Cited by
612
References
203
Citations by year
2026: 16 · 2025: 17 · 2024: 20 · 2023: 30 · 2022: 19 · 2021: 30 · 2020: 10 · 2019: 22 · 2018: 28 · 2017: 27 · 2016: 23 · 2015: 37 · 2014: 24 · 2013: 29 · 2012: 27
FWCI
3.58
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Progress in Neuro-Psychopharmacology and Biological Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
selective serotonin reuptake inhibitors, serotonin, serotonin receptors, antidepressant mechanism, adverse drug reactions, drug-drug interactions, cytochrome P450, therapeutic drug monitoring, tricyclic antidepressants, depression, obsessive-compulsive disorder, social anxiety disorder, anorexia nervosa, bulimia nervosa, eating disorders, sleep disorders
MeSH terms
Adolescent, Adult, Age Factors, Aged, Anxiety Disorders, Feeding and Eating Disorders, Child, Depressive Disorder, Female, Humans, Male, Middle Aged, Pregnancy, Pregnancy Complications, Substance Withdrawal Syndrome, Suicide, Attempted, Selective Serotonin Reuptake Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review